Clarient to Present at Two Investor Conferences in August

ALISO VIEJO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the biopharmaceutical industry, today announced that the Company is scheduled to make investor presentations at two investor conferences in the month of August.

• Canaccord Genuity 30th Annual Growth Conference at 2:00 p.m. EDT on Tuesday, August 10 in Boston, MA. The conference will be held August 10-12 at the InterContinental Boston.
• 2010 Southern California Investor Conference at 9:00 a.m. PDT on Tuesday, August 17 at The Island Hotel in Newport Beach, CA.

A live webcast of each presentation will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the Canaccord Genuity presentation will also be available for a period of 90 days from the date of the presentation at http://www.clarientinc.com/investor.

About Clarient

Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals, and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services for pathologists and oncologists. Clarient also provides a complete complement of commercial services to biopharmaceutical companies and other research organizations, including diagnostic testing services, development of companion diagnostics, and clinical trial support. Clarient also develops and markets new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung, ovarian, and colon cancers, and leukemia/lymphoma. Clarient's customers are connected to its Internet-based portal, PATHSiTE®, which delivers high resolution images and critical interpretive reports based on its diagnostic testing. www.clarientinc.com

SOURCE Clarient, Inc.